Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | DRD3 | P35462 | 4/20 | 0.43 |
| ▸ | GRM6 | O15303 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17389297 | 0.84 | MAPT (0.51) | MAPTBRD4S1PR1S1PR5PDK1 | |
| SCHEMBL17631636 | 0.84 | MAPT (0.51) | MAPTBRD4S1PR1S1PR5PDK1 | |
| SCHEMBL19281632 | 0.84 | MAPT (0.51) | MAPTBRD4S1PR1S1PR5PDK1 | |
| SCHEMBL22038592 | 0.81 | MAPT (0.62) | MAPTDRD2DRD3 | |
| SCHEMBL26186740 | 0.81 | MAPT (0.58) | MAPTBRD4S1PR1S1PR5PDK1 | |
| SCHEMBL9543098 | 0.81 | MAPT (0.50) | MAPTBRD4S1PR1S1PR5PDK1 | |
| SCHEMBL20135465 | 0.81 | MAPT (0.58) | MAPTBRD4S1PR1S1PR5PDK1 | |
| SCHEMBL26186803 | 0.81 | MAPT (0.58) | MAPTBRD4S1PR1S1PR5PDK1 | |
| SCHEMBL17986812 | 0.81 | MAPT (0.58) | MAPTBRD4S1PR1S1PR5PDK1 | |
| Hydrochloric Acid SCHEMBL20135692 | 0.79 | MAPT (0.56) | MAPTBRD4S1PR1S1PR5PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150191476-A1 | Imidazotriazinone Compounds | FORUM PHARMACEUTICALS INC. | 2015-07-09 | — | — | US | disclosed |
| EP-2152712-B1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER (US) | 2012-01-11 | — | — | EP | disclosed |
| US-7964607-B2 | Pyrazolo[3,4-d]pyrimidine compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2152712-A1 | AMINO-HETEROCYCLIC COMPOUNDS | Pfizer Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC | 2009-01-29 | — | — | US | disclosed |
| WO-2008139293-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PDE9A, PDE2A, PDE10A | MAPT 372/4885BRD4 1184/4885S1PR1 3298/4885 |
| US-20150191476-A1 | Imidazotriazinone Compounds | PDE9A, PDE12, PDE4A | MAPT 3164/4885BRD4 914/4885S1PR1 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.